Crossmark

PF-06438179/GP1111: An Infliximab Biosimilar

Crossref DOI link: https://doi.org/10.1007/s40259-018-0310-5

Published Online: 2018-10-04

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Al-Salama, Zaina T.
License Information

Text and Data Mining valid from 2018-10-04
More Information

Article History

First Online: 4 October 2018

Change Date: 15 November 2018

Change Type: Correction

Change Details: The article PF-06438179/GP1111: An Infliximab Biosimilar, written by Zaina T. Al-Salama

Compliance with Ethical Standards

:

: The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of GP1111 was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit. Zaina T. Al-Salama is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.